Ariad Pharma (ARIA) Posts Q4 Loss of 40c/Share; Offers FY14 Outlook
Tweet Send to a Friend
Ariad Pharma (NASDAQ: ARIA) reported Q4 EPS of ($0.40), $0.07 better than the analyst estimate of ($0.47). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
